Sanofi India Limited Codeine Export Data — India (DGFT 2022–2026)

Name: Sanofi India Limited Codeine Export Records India — #4 Exporter, 75 Shipments, $3.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Codeine

India Pharmaceutical Trade Intelligence

$109.2M30 Suppliers35 CountriesHS 30049069

ExportsIndia → UNITED KINGDOM57.2%India → SOUTH AFRICA30.5%

ImportsUNITED KINGDOM → India$1.3K AUSTRALIA → India$1.2K

#1 Supplier: WOCKHARDT LIMITED #1 Buyer: WOCKHARDT UK

Sanofi India Limited — Codeine Exporter #4 | $3.8M Trade Value | TransData Nexus | TransData Nexus

Sanofi India Limited — Codeine Exporter Profile

Indian Pharmaceutical Exporter · #4 for Codeine · $3.8M export value · DGFT Verified

Sanofi India Limited is the #4 Indian exporter of Codeine with $3.8M in export value and 75 verified shipments. Sanofi India Limited holds a 3.4% market share in Codeine exports across 2 countries. The company exports 4 pharmaceutical products worth $9.0M across 4 therapeutic categories.

Sanofi India Limited — Codeine Export Profile: Buyers & Destinations

Sanofi India Limited Codeine export treemap — buyers and destination countries | TransData Nexus

Where Does Sanofi India Limited Export Codeine?

Country	Value	Shipments	Share
AUSTRALIA	$3.1M	74	98.4%
IRELAND	$50.0K	1	1.6%

Sanofi India Limited exports Codeine to 2 countries. The largest destination is AUSTRALIA accounting for 98.4% of Sanofi India Limited's Codeine shipments. These destinations reflect Sanofi India Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Codeine from Sanofi India Limited?

What Codeine Formulations Does Sanofi India Limited Export?

Product Description / Formulation	Value	Shipments
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS ( 295741 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) P	$140.3K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS ( 293972 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) P	$139.7K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS ( 295845 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PTBS	$139.1K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS (294673 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PA	$136.4K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS (294327 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PA	$135.9K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS (292880 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PA	$135.5K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS ( 196729 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PTBS	$98.7K	3
PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG TABLETS (196905 PACKX 20) EXEMPTED MATERIAL (W/O WASTAGE) PA	$96.4K	3
PHARMACEUTICAL PRODUCTS - MERSYNDOL FORTE 5-30-450MG TABLETS (87391 PACK X 20) EXEMPTED MATERIAL (W/O WASTAGE CODEINE PHTBS	$60.7K	3
PHARMACEUTICAL PRODUCTS - MERSYNDOL FORTE 5-30-450MG TABLETS (87629 PACK X 20) Exempted Material (W/O Wastage) CODEINE P	$60.5K	3

Sanofi India Limited exports 55 distinct Codeine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL PRODUCTS - APX-PARACETAMOL/CODEINE 500-30MG T with 3 shipments worth $140.3K.

How Does Sanofi India Limited Compare to Nearest Codeine Exporters?

Exporters ranked immediately above and below #4 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	WOCKHARDT LIMITED	$9.6M	191	1	$50.0K
3	MEDREICH LIMITED	$7.3M	145	4	$50.0K
4	SANOFI INDIA LIMITED ★	$3.8M	75	2	$50.0K
6	CIPLA LIMITED	$1.4M	211	3	$6.7K
5	PRG PHARMA PRIVATE LIMITED	$750.0K	15	2	$50.0K

Sanofi India Limited ranks #4 among 30 Indian Codeine exporters. Average shipment value of $50.0K compared to the market average of $2.0M. The closest competitors by value are WOCKHARDT LIMITED and MEDREICH LIMITED.

Which Indian Ports Ship Codeine Exports?

Port	Shipments	% Share
BANGALORE ICD	657	36.8%
BANGALORE ICD (INWFD6)	205	11.5%
NHAVA SHEVA SEA (INNSA1)	171	9.6%
JNPT/ NHAVA SHEVA SEA	135	7.6%
JNPT	114	6.4%
SAHAR AIR	80	4.5%
Bangalore	59	3.3%
Bangalore ICD	34	1.9%

Geopolitical & Trade Policy Impact on Sanofi India Limited's Codeine Exports

Recent geopolitical developments have introduced significant challenges for Indian pharmaceutical exporters like Sanofi India. The escalation of conflicts in the Middle East, particularly around the Red Sea and Suez Canal, has disrupted key shipping routes. Major carriers have suspended or restricted transits, leading to extended transit times by 10–20 days and increased freight rates by 40–50% on India–Europe routes. (livemint.com) These disruptions pose risks to the timely delivery of temperature-sensitive pharmaceuticals, potentially affecting product efficacy and market competitiveness.

In the United States, the implementation of tariffs on pharmaceutical imports, including a 25% reciprocal tariff and an additional 25% penalty tied to India's energy policies, has created an uncertain trade environment. Although pharmaceuticals have been exempt from some of these tariffs, the potential for future escalations remains a concern. (en.wikipedia.org) Additionally, the European Union's stringent regulatory frameworks, such as the Falsified Medicines Directive, necessitate rigorous compliance measures, adding complexity to market entry and sustainability for exporters like Sanofi India.

Sanofi India Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Sanofi India has consistently adhered to guidelines set by the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Union's Good Manufacturing Practices (EU GMP). This commitment ensures product quality and facilitates access to global markets. However, evolving regulatory requirements, such as the EU's Falsified Medicines Directive, demand continuous adaptation and investment in compliance infrastructure. For instance, the directive's serialization and traceability mandates require significant technological upgrades, impacting operational costs and necessitating strategic planning.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Codeine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Sanofi India Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 75 individual customs records matching Sanofi India Limited exporting Codeine, covering 55 formulations to 2 countries via 4 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 35+ countries, 82+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

SANOFI-AVENTIS AUSTRALIA PTY LTD	AUSTRALIA	$2.5M	60
SANOFI AVENTIS AUSTRALIA PTY LTD	AUSTRALIA	$300.0K	6
SANOFI-AVENTIS AUSTRALIA PTY LIMITED	AUSTRALIA	$259.8K	8
PHOENIX LABS C/O,	IRELAND	$50.0K	1

Codeine

Codeine

Sanofi India Limited — Codeine Exporter Profile

Sanofi India Limited — Codeine Export Profile: Buyers & Destinations

Where Does Sanofi India Limited Export Codeine?

Who Are the Top Buyers of Codeine from Sanofi India Limited?

What Is India's Total Codeine Export Value and How Much Does Sanofi India Limited Contribute?

What Is the Average Shipment Value for Sanofi India Limited's Codeine Exports?

How Does Sanofi India Limited Compare to Other Indian Codeine Exporters?

What Codeine Formulations Does Sanofi India Limited Export?

Regulatory Requirements: Exporting Codeine to Key Markets

Australia — TGA

How Does Sanofi India Limited Compare to Nearest Codeine Exporters?

Which Indian Ports Ship Codeine Exports?

Geopolitical & Trade Policy Impact on Sanofi India Limited's Codeine Exports

Sanofi India Limited — Regulatory Compliance & Quality Standards

About Sanofi India Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Codeine Export Data from Sanofi India Limited

Codeine Stats

Company Overview

Top Products by Sanofi India Limited

Related Analysis

Need Detailed Export Data?

Data Source